Evento sobre alergias cutáneas (SAM) 2025 de la EAACI-ESCD: innovaciones pioneras en alergias cutáneas y dermatitis de contacto
February 04, 2025 03:00 ET
|
European Academy of Allergy and Clinical Immunology
ZÚRICH, Feb. 04, 2025 (GLOBE NEWSWIRE) -- El comité organizador se complace en anunciar la séptima edición del Evento sobre alergias cutáneas (SAM) de la EAACI-ESCD, el evento más importante de...
EAACI-ESCD Skin Allergy Meeting (SAM) 2025: Inovações pioneiras nas alergias da pele e na dermatite de contacto
February 04, 2025 03:00 ET
|
European Academy of Allergy and Clinical Immunology
ZURIQUE, Feb. 04, 2025 (GLOBE NEWSWIRE) -- A comissão organizadora tem o prazer de anunciar a sétima edição da EAACI-ESCD Skin Allergy Meeting (SAM), o principal evento da Europa dedicado às...
EAACI-ESCD Skin Allergy Meeting (SAM) 2025: Pioneering Innovations in Skin Allergy and Contact Dermatitis
February 04, 2025 03:00 ET
|
European Academy of Allergy and Clinical Immunology
ZURICH, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The Organising Committee is delighted to announce the seventh edition of the EAACI-ESCD Skin Allergy Meeting (SAM), Europe’s leading event dedicated to skin...
Global Allergy Diagnostics and Therapeutics Market Size/Share Worth USD 78,036.1 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 18, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Allergy Diagnostics and Therapeutics Market Size, Trends and Insights By Product...
EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT 2024
November 13, 2024 05:43 ET
|
European Academy of Allergy and Clinical Immunology
On 21 November 2024, during the opening day of EAACI FAAM-EUROBAT 2024 in Athens, Greece, EAACI proudly launches World Anaphylaxis Day. Join us!
Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
November 05, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management
October 30, 2024 07:26 ET
|
European Academy of Allergy and Clinical Immunology
The European Academy of Allergy and Clinical Immunology (EAACI) has released updated "Clinical Guidelines on the Management of IgE-mediated Food Allergy."
Food Allergy Market Report 2024: $40+ Billion Industry to Grow at a CAGR of 6.7% During 2025-2030 - Innovations in Immunotherapy allergology Open New Avenues in Treatment
October 22, 2024 09:00 ET
|
Research and Markets
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Food Allergy Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Allergen Source, Treatment Type, Channel, Region, By...
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
October 07, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
September 27, 2024 09:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...